單國洪先生于2017年9月18日起出任武田中國總裁，常駐上海，全面負責武田中國（包括香港、澳門地區(qū)）的整體戰(zhàn)略及業(yè)務增長，同時也是武田成長與新興市場管理層委員。在他的領導下，武田中國成功實現(xiàn)了戰(zhàn)略轉(zhuǎn)型，近年來業(yè)務高速發(fā)展，中國市場已成為武田全球最重要的戰(zhàn)略市場之一。 單國洪先生擁有逾二十年以上行業(yè)管理經(jīng)驗，對中國的醫(yī)療及制藥行業(yè)有著獨到的洞察和深刻的認知。在加入武田之前，他曾出任輝瑞創(chuàng)新集團中國區(qū)總經(jīng)理、阿斯利康中國區(qū)副總裁等跨國藥企高級管理職位；同時還曾擔任輝瑞全球腫瘤委員會，阿斯利康全球呼吸領域品牌委員會成員等職務。憑借其豐富的國際化管理經(jīng)驗以及深刻的行業(yè)洞察力，他曾成功地領導了腫瘤、免疫、罕見病及疫苗等多個疾病領域的創(chuàng)新產(chǎn)品在中國大陸、香港及澳門地區(qū)的獲批與上市，使這些創(chuàng)新藥品更早惠及中國患者。 作為一名醫(yī)療行業(yè)資深專業(yè)人士，單國洪先生活躍于各項社會事務，并擔任多個社會職務。他是中國癌癥基金會和中國醫(yī)藥生物技術(shù)協(xié)會的常務理事，中國外商投資企業(yè)協(xié)會藥品研制和開發(fā)行業(yè)委員會（RDPAC）執(zhí)行委員會委員，也是復旦大學管理學院的校友導師，并擁有美國華盛頓大學和復旦大學高級工商管理碩士（EMBA）學位。 ? ?Sean Shan has been appointed as President of Takeda China since 18 September 2017, taking full responsibilities for Takeda’s overall strategy and business development in China, including Hong Kong and Macao. In addition to his role as China head, he also sits on the Leadership Committee of Growth & Emerging Markets of Takeda, representing China market. Under his leadership Takeda China has accelerated its strategic transformation with great success recently. The businesses keep a fast pace with strong growth across broad therapeutic areas. China now is seen one of the most important strategic markets at Takeda worldwide. ? ?Bringing his over 20 years’ experiences in pharmaceutical industry in China, Sean is a seasoned executive with versatile functional expertise in marketing and sales, business development. Before joining Takeda, he took several roles as senior executive in the leading MNCs, such as General Manager of Innovation Healthcare of Pfizer China, Vice President of Astra Zeneca China etc. Apart from his country leadership role, he also held global key positions as the member of Global Oncology Council of Pfizer, Global Respiratory Brand Council of Astra Zeneca. Combining his international leadership experience and in-depth functional expertise in pharmaceutical industry, he has been leading several new drugs approval and launch across mainland China, Hong Kong and Macao, with specific to oncology, immunology, rare disease and vaccine. More Chinese patients are benefitting now from these innovative medicines. ? ?As a senior healthcare professional Sean has been proactively taking social responsibilities and roles. He is now a standing member of the board of China Cancer Foundation and China Medical and Biotechnological Association, executive committee member of RDPAC, and alumina tutor of Management School of Fudan University. He possesses EMBA from University of Washington and Fudan University. Sean and his family are based in Shanghai. |